These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38510044)

  • 1. Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study.
    Li Y; Li H; Xiang Z
    Heliyon; 2024 Mar; 10(6):e27599. PubMed ID: 38510044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib.
    Lin Y; Zheng X; Chen Y; Nian Q; Lin L; Chen M
    Heliyon; 2024 Mar; 10(6):e27529. PubMed ID: 38496864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
    Chai S; Zhan JL; Zhao LM; Liu XD
    Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse events associated with eteplirsen: A disproportionality analysis using the 2016-2023 FAERS data.
    Dai Z; Wang G; Zhang J; Zhao Q; Jiang L
    Heliyon; 2024 Jul; 10(13):e33417. PubMed ID: 39027557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpelisib-Induced Diabetic Ketoacidosis: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System and Review of the Literature.
    Ziegengeist JL; Elmes JB; Strassels SA; Patel JN; Moore DC
    Clin Breast Cancer; 2024 Jun; 24(4):e204-e209. PubMed ID: 38245400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study.
    Yuan T; Li F; Hou Y; Guo H
    Front Pharmacol; 2023; 14():1266890. PubMed ID: 38074150
    [No Abstract]   [Full Text] [Related]  

  • 9. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Chen W; Cai P; Zou W; Fu Z
    Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database.
    Chen X; Wei L; Chi L; Guo X; Chen C; Guo Z; Liang J; Zheng Y; He J; Ye X
    Br J Clin Pharmacol; 2022 May; 88(5):2180-2189. PubMed ID: 34786743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
    Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
    Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
    Shu Y; Chen J; Ding Y; Zhang Q
    Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A real-world disproportionality analysis of sacubitril/valsartan: data mining of the FDA adverse event reporting system.
    Wang Y; Liu X
    Front Pharmacol; 2024; 15():1392263. PubMed ID: 39193332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
    Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
    Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
    Li Z; Guo C; Liu X; Qiu Z; Zhang R
    Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
    [No Abstract]   [Full Text] [Related]  

  • 16. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system.
    Zhao B; Fu Y; Cui S; Chen X; Liu S; Luo L
    Front Pharmacol; 2024; 15():1333662. PubMed ID: 38533254
    [No Abstract]   [Full Text] [Related]  

  • 18. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-marketing safety of anti-IL-5 monoclonal antibodies (mAbs): an analysis of the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang M; Cheng Q; Shi X; Sun MH
    Expert Opin Drug Saf; 2024 Mar; 23(3):353-362. PubMed ID: 37610085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.